What should you know before buying stock in AbCellera Biologics Inc (ABCL)

AbCellera Biologics Inc (NASDAQ: ABCL) is -54.29% lower on its value in year-to-date trading and has touched a low of $2.34 and a high of $6.05 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ABCL stock was last observed hovering at around $2.56 in the last trading session, with the day’s gains setting it 0.05%.

Currently trading at $2.61, the stock is 1.32% and -4.39% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.56 million and changing 1.95% at the moment leaves the stock -34.61% off its SMA200. ABCL registered -44.59% loss for a year compared to 6-month loss of -42.38%. The firm has a 50-day simple moving average (SMA 50) of $2.7209 and a 200-day simple moving average (SMA200) of $3.980725.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The stock witnessed a 1.95% gain in the last 1 month and extending the period to 3 months gives it a -11.82%, and is 0.77% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.28% over the week and 5.98% over the month.

AbCellera Biologics Inc (ABCL) has around 586 employees, a market worth around $769.09M and $33.06M in sales. Profit margin for the company is -463.77%. Distance from 52-week low is 11.78% and -56.90% from its 52-week high. The company has generated returns on investments over the last 12 months (-13.02%).

with sales reaching $7.95M over the same period.The EPS is expected to grow by 6.97% this year, but quarterly earnings will post -11.60% year-over-year. Quarterly sales are estimated to shrink -32.90% in year-over-year returns.

AbCellera Biologics Inc (ABCL) Top Institutional Holders

214.0 institutions hold shares in AbCellera Biologics Inc (ABCL), with institutional investors hold 57.71% of the company’s shares. The shares outstanding are 290.82M, and float is at 206.59M with Short Float at 8.15%. Institutions hold 41.52% of the Float.

The top institutional shareholder in the company is BAKER BROS. ADVISORS LP with over 27.53 million shares valued at $81.48 million. The investor’s holdings represent 9.4033% of the ABCL Shares outstanding. As of 2024-06-30, the second largest holder is BAILLIE GIFFORD & CO with 21.91 million shares valued at $64.86 million to account for 7.4852 of the shares outstanding. The other top investors are VOYA INVESTMENT MANAGEMENT LLC which holds 10.63 million shares representing 3.6322% and valued at over $31.47 million, while CAPITAL WORLD INVESTORS holds 1.817 of the shares totaling 5.32 million with a market value of $15.74 million.